Apogee Therapeutics, Inc. (NASDAQ: APGE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
134.19
+0.08+0.06%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 7.07% | Shs Outstand | 61.88M | Perf Week | 0.01% |
| Market Cap | 8.30B | Forward P/E | - | EPS next Y | -5.54 | Insider Trans | -6.16% | Shs Float | 57.17M | Perf Month | 0.52% |
| Enterprise Value | 7.25B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 7.23% | Perf Quarter | 60.61% |
| Income | -256.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 1.65 | Perf Half Y | 104.46% |
| Sales | 0.00 | P/B | 6.61 | EPS next Y | -24.72% | ROA | -21.23% | Short Interest | 4.13M | Perf YTD | 77.78% |
| Book/sh | 20.30 | P/C | 7.83 | EPS next 5Y | - | ROE | -32.64% | 52W High | 134.46 -0.20% | Perf Year | 255.47% |
| Cash/sh | 17.13 | P/FCF | - | EPS past 3/5Y | - | ROIC | -24.15% | 52W Low | 34.34 290.77% | Perf 3Y | 546.70% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 0.16% 0.23% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -31.21% | Oper. Margin | 0.00% | ATR (14) | 1.07 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 32.59 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 78.77 | Recom | 2.73 |
| Dividend Gr. 3/5Y | - | Current Ratio | 32.59 | EPS Q/Q | -11.58% | SMA20 | 0.11% | Beta | 0.92 | Target Price | 125.52 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | - | SMA50 | 16.83% | Rel Volume | 0.91 | Prev Close | 134.11 |
| Employees | 261 | LT Debt/Eq | 0.01 | Earnings | Aug 10 | SMA200 | 60.26% | Avg Volume | 2.62M | Price | 134.19 |
| IPO Date | Jul 14, 2023 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.59% - | Net Debt/EBITDA | 1.63 | Volume | 2,377,912 | Change | 0.06% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-24-26 | Reiterated | Stifel Nicolaus | $133 → $135 | |
| Jun-24-26 | Downgrade | Stifel | Buy → Hold | |
| Jun-24-26 | Downgrade | TD Cowen | Buy → Hold | |
| Jun-24-26 | Downgrade | Guggenheim | Buy → Neutral | |
| Jun-24-26 | Downgrade | Mizuho | Outperform → Neutral | $135 |
| Jun-23-26 | Downgrade | Deutsche Bank | Buy → Hold | $135 |
| Jun-23-26 | Downgrade | Citigroup | Buy → Neutral | |
| Jun-23-26 | Reiterated | RBC Capital | Sector Perform | $97 → $135 |
| Jun-23-26 | Downgrade | UBS | Buy → Neutral | $135 |
| Jun-23-26 | Downgrade | Wedbush | Outperform → Neutral |
Latest News
Jul-31-26
Jul-30-26
Jul-30-2601:00PM
Jul-28-26
Jul-28-2610:41AM
Jul-24-26
Jul-21-26
Jul-13-26
Jul-08-26
Jul-06-26
Jul-02-26
Jul-02-2605:34AM
Jun-30-26
Jun-30-2603:45PM
11:55AM
U.S. Equity Markets: Lots Of Gambling Going OnSeekingAlpha
Jun-29-26
Jun-26-26
Jun-26-2601:52PM
Jun-24-26
10:24AM
Company
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 1 | 0 | 0 | 0 | |
| Gross Profit | -1 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 71 | 49 | 25 | 3 | |
| Research and Development | 215 | 168 | 68 | 28 | |
| Other Operating Expense | -2 | 0 | 0 | 0 | |
| Operating Income | -286 | -217 | -93 | -31 | |
| Interest Expense | 0 | 0 | 0 | 9 | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | 30 | 35 | 9 | 0 | |
| Net Income Before Taxes | -256 | -182 | -84 | -40 | |
| Income Taxes | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -256 | -182 | -84 | -40 | |
| Net Income From Continuing Operations | -256 | -182 | -84 | -40 | |
| Net Income | -256 | -182 | -84 | -40 | |
| EPS (Recurring) | -4.22 | -3.30 | -1.66 | -0.79 | |
| EPS (Basic, Before Extraordinaries) | -4.22 | -3.30 | -1.66 | -0.79 | |
| EPS (Diluted) | -4.22 | -3.30 | -1.66 | -0.79 | |
| EBITDA | -254 | -182 | -75 | -40 | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | |
| Gross Margin | — | — | — | — | |
| Operating Margin | — | — | — | — | |
| Net Margin | — | — | — | — | |
| Shares Outstanding | 61 | 55 | 51 | 51 | |
| Market Capitalization | 4,604 | 2,492 | 1,425 | — | |
| Operating Lease Expense | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | Jul 08 '26 | Sale | 133.63 | 20,000 | 2,672,600 | 995,987 | Jul 10 |
| Dambkowski Carl | Chief Medical Officer | Jul 01 '26 | Option Exercise | 22.86 | 4,125 | 94,298 | 183,373 | Jul 02 |
| Dambkowski Carl | Chief Medical Officer | Jul 01 '26 | Sale | 132.74 | 5,500 | 730,070 | 177,873 | Jul 02 |
| Dambkowski Carl | Chief Medical Officer | Jun 22 '26 | Sale | 132.60 | 26,400 | 3,500,640 | 179,248 | Jun 24 |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | Jun 22 '26 | Sale | 132.54 | 80,000 | 10,603,200 | 1,015,987 | Jun 24 |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | Jun 10 '26 | Sale | 83.38 | 20,000 | 1,667,621 | 1,095,987 | Jun 12 |
| Dambkowski Carl | Chief Medical Officer | Jun 03 '26 | Sale | 78.71 | 5,500 | 432,905 | 205,648 | Jun 05 |
| Dambkowski Carl | Chief Medical Officer | Jun 03 '26 | Option Exercise | 22.86 | 4,125 | 94,298 | 211,148 | Jun 05 |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | May 13 '26 | Sale | 82.09 | 20,000 | 1,641,711 | 1,115,987 | May 15 |
| Dambkowski Carl | Chief Medical Officer | May 06 '26 | Option Exercise | 22.86 | 4,125 | 94,298 | 212,523 | May 08 |
| Dambkowski Carl | Chief Medical Officer | May 06 '26 | Sale | 84.14 | 5,500 | 462,784 | 207,023 | May 08 |
| Henderson Jane | Chief Financial Officer | May 01 '26 | Sale | 82.04 | 2,000 | 164,080 | 173,371 | May 04 |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | Apr 16 '26 | Option Exercise | 22.86 | 3,000 | 68,580 | 1,135,987 | Apr 20 |
| Henderson Jane | Chief Financial Officer | Apr 16 '26 | Sale | 90.00 | 2,000 | 180,000 | 175,371 | Apr 17 |
| HENDERSON MICHAEL THOMAS | Chief Executive Officer | Apr 08 '26 | Sale | 82.58 | 20,000 | 1,651,664 | 1,132,987 | Apr 10 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.